Most recently acquired 330 shares in Feb 2019. Currently holds stock worth $8.99M. Has donated $415.78K in stock to charitable causes.
Compensation History
Annual executive compensation data for Gregg Alton, including salary, bonuses, and stock awards.
Year
2019
Total Compensation
$0.00
Salary
$0.00
Bonus
$0.00
Other
$0.00
Salary
$0.00Board Justification
The compensation philosophy emphasizes pay-for-performance, aligning CEO compensation closely with market median pay and performance-based compensation.
Bonus
$0.00Board Justification
The annual bonus plan is contingent upon performance in a number of pre-established categories including pipeline and product objectives, financial criteria, and organizational goals, but specific amounts for 2019 are not detailed in the provided text.
Other Compensation
$0.00Board Justification
No specific details on other compensation for 2019 are provided in the text.
Restricted Stock
Board Justification
No specific details on vested stock for 2019 are provided in the text.
Performance Metrics
The CEO's bonus is tied entirely to corporate objectives, with annual pay reflecting a significant emphasis on performance-based compensation.
Gregg Alton
Ex-CEO of Gilead Sciences
Education
J.D. from Stanford Law School
Field of Expertise
Legal & Compliance - Legal
Sector of Economy
Healthcare
Born
June 1, 1966 - 59 years ago
CEO of Gilead Sciences for
0 years 2 months (Jan 2019 - Mar 2019)
Previous Experience
General Counsel and Chief Patient Officer at Gilead Sciences
Holdings
Track Gregg Alton's stock holdings and portfolio value over time.
Total Stock Sold
$157.41M
$157.41M
2,782,435 GILD shares
What if they kept their stock?
If Gregg Alton didn't sell their stock, today they would have:
Extra GILD2,782,435 shares worth $337.29M.
This is 114.27% and $179.87M more than what they got when they sold the stock.
Charitable Transactions
3,430 shares
GILD
Recent Charitable Transactions
1,430 shares
GILD
Feb 21, 2017
Charity
1,000 shares
GILD
Dec 22, 2014
Charity
1,000 shares
GILD
Aug 30, 2013
Charity
Insider Trading
Gregg Alton's recent stock transactions, purchases, and sales filed with the SEC.
$18.96K
GILD at $57.45/share
Feb 15, 2019
Received
19,151 shares
GILD
Feb 6, 2019
Received
$1.97M
GILD at $78.66/share
Mar 1, 2018
Sale
$422.55K
GILD at $20.78/share
Feb 15, 2018
Received
$1.18M
GILD at $81.54/share
Feb 20, 2018
Sale
$2.09M
GILD at $83.47/share
Feb 1, 2018
Sale
$2.37M
GILD at $79.00/share
Jan 11, 2018
Sale
$1.10M
GILD at $73.40/share
Jan 2, 2018
Sale
$1.12M
GILD at $74.83/share
Dec 1, 2017
Sale
Rivals
Compare Gregg Alton with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M
Marianne De Backer, MSc, Ph.D., MBA
CEO of Vir Biotechnology, Inc.
2023 Compensation
Stock
$5.80M
Salary
$675.00K
Bonus
$855.36K
Other
$437.18K
Total Holdings
$556.68K
John L. Higgins
CEO of Ligand Pharmaceuticals
2022 Compensation
Stock
$0.00
Salary
$730.46K
Bonus
$0.00
Other
$0.00
Total Holdings
$5.64M